The impact of the COVID‐19 pandemic on perioperative chemotherapy for breast cancer

Background Since it was first reported in December 2019, coronavirus disease 2019 (COVID‐19) spread rapidly across the globe resulting in a pandemic. As of August 2022, seven outbreak peaks have been confirmed in Tokyo, and the numbers of new cases in the fifth and later outbreak periods have been f...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2023-06, Vol.12 (11), p.12095-12105
Main Authors: Baba, Kaede, Kawamoto, Megumi, Mamishin, Kanako, Uematsu, Mao, Kiyohara, Hikari, Hirota, Akira, Takahashi, Nobuyuki, Fukuda, Misao, Kusuhara, Shota, Nakajima, Hiromichi, Funasaka, Chikako, Nakao, Takehiro, Kondoh, Chihiro, Harano, Kenichi, Matsubara, Nobuaki, Naito, Yoichi, Hosono, Ako, Kawasaki, Toshikatsu, Mukohara, Toru
Format: Article
Language:English
Subjects:
adjuvant chemotherapy
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - epidemiology
Breast Neoplasms - surgery
Cancer therapies
Chemotherapy
Clinical medicine
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 vaccines
Data collection
Female
Fever
Health facilities
Hospitals
Humans
Immunization
Infections
Lymphatic system
Medical prognosis
neoadjuvant chemotherapy
Oncology
Pandemics
Patients
Retrospective Studies
SARS-CoV-2
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Since it was first reported in December 2019, coronavirus disease 2019 (COVID‐19) spread rapidly across the globe resulting in a pandemic. As of August 2022, seven outbreak peaks have been confirmed in Tokyo, and the numbers of new cases in the fifth and later outbreak periods have been far greater than in the preceding periods. This retrospective study examined the impact of the COVID‐19 pandemic on perioperative chemotherapy for breast cancer. Methods Patients with breast cancer who received perioperative chemotherapy at the National Cancer Center Hospital East were divided into 2 groups: 120 and 384 patients who started chemotherapy before and during the pandemic, respectively. The incidence of critical events that had potential detrimental effects on the prognosis, such as start of adjuvant chemotherapy ≥91 days after surgery and relative dose intensity of chemotherapy
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.5898